menatetrenone

Also Known As:

(E,E,E)-isomer of menatetrenone; 2-methyl-3-all-trans-tetraprenyl-1,4-naphthoquinone; 2-methyl-3-trans-tetraprenyl-1,4-naphthoquinone; Kefton-2; menaquinone 4; menaquinone-4; vitamin K2(20); vitamin MK-4

Networked: 123 relevant articles (11 outcomes, 19 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Iwamoto, Jun: 13 articles (01/2021 - 09/2003)
2.	Sato, Yoshihiro: 9 articles (01/2021 - 01/2004)
3.	Takeda, Tsuyoshi: 9 articles (01/2021 - 09/2003)
4.	Komai, Michio: 6 articles (09/2021 - 12/2005)
5.	Shirakawa, Hitoshi: 5 articles (09/2021 - 09/2011)
6.	Matsumoto, Hideo: 5 articles (01/2018 - 01/2009)
7.	Miyazawa, Keisuke: 5 articles (09/2010 - 09/2003)
8.	Ohyashiki, Kazuma: 5 articles (09/2010 - 09/2003)
9.	Eguchi, Yuichiro: 4 articles (12/2012 - 02/2006)
10.	Mizuta, Toshihiko: 4 articles (12/2012 - 02/2006)

Related Diseases

1.	Hip Fractures (Intertrochanteric Fractures) 01/01/2009 - "The present meta-analysis of three RCTs suggests that there is efficacy for menatetrenone treatment against non-vertebral and hip fractures among patients with neurological diseases. " 01/01/2009 - "A literature search was conducted on PubMed from January 1995 to July 2008 to identify randomized controlled trials (RCTs) of use of menatetrenone against non-vertebral and hip fractures in patients with neurological diseases. " 01/01/2009 - "According to the meta-analysis, the overall relative risks (95% confidence intervals) for non-vertebral and hip fractures with menatetrenone treatment compared with non-treatment were 0.13 (0.05, 0.35) and 0.14 (0.05, 0.43), respectively, in patients with neurological diseases. " 01/01/2018 - "Retraction Note to: Efficacy of Menatetrenone (Vitamin K2) against Non-Vertebral and Hip Fractures in Patients with Neurological Diseases : Meta-Analysis of Three Randomized, Controlled Trials." 01/01/2009 - "The purpose of the present study was to clarify the efficacy of menatetrenone (vitamin K(2)) against non-vertebral and hip fractures in patients with neurological diseases. "
2.	Metabolic Bone Diseases (Osteopenia) 02/15/2002 - "Finally, these findings implicated the therapeutic usefulness of menatetrenone on a moderate degree of bone abnormality such as drug-induced osteopenia." 01/01/2021 - "Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients. " 01/01/2004 - "Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients. " 09/01/1998 - "Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients." 05/01/2003 - "Effects of menatetrenone on the bone and serum levels of vitamin K2 (menaquinone derivatives) in osteopenia induced by phenytoin in growing rats."
3.	Stroke (Strokes) 09/01/1998 - "In a random and prospective study, of 108 hemiplegic patients following stroke, 54 received 45 mg menatetrenone daily (MK-4 group, n = 54) for 12 months, and the remaining 54 (untreatment group) did not. " 01/01/2021 - "Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients. " 01/01/2004 - "Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients. " 09/01/1998 - "Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients."
4.	Osteoporosis 01/01/1999 - "Administration of menatetrenone at a dose effective in improving osteoporosis may also be useful in restoring hematopoiesis in MDS patients, possibly by way of inducing differentiation." 10/01/2021 - "Correction to: The efficacy and safety of menatetrenone in the management of osteoporosis: a systematic review and meta-analysis of randomized controlled trials." 06/01/2019 - "PubMed, Cochrane Library, Embase, ClinicalTrials.gov , and three Chinese literature databases (CNKI, CBM, Wanfang) were searched for relevant randomized controlled trials (RCTs) published before October 5, 2017, comparing menatetrenone with other anti-osteoporotic drugs or placebo in treating osteoporosis. " 06/01/2019 - "The efficacy and safety of menatetrenone in the management of osteoporosis: a systematic review and meta-analysis of randomized controlled trials." 05/16/2014 - "The present review study aimed to clarify the effect of menatetrenone on the skeleton in postmenopausal women with osteoporosis, by reviewing the results of randomized controlled trials (RCTs) in the literature. "
5.	Postmenopausal Osteoporosis 01/01/2014 - "Menatetrenone is an effective and safe choice in the treatment of postmenopausal osteoporosis in Chinese women." 01/01/2016 - "Objective Vitamin K2 (menatetrenone) is an effective treatment for patients with postmenopausal osteoporosis. " 09/30/2023 - "Correction to: Menatetrenone (Vitamin K2) and Bone Quality in the Treatment of Postmenopausal Osteoporosis." 01/01/2020 - "Expression of Concern: "Menatetrenone (Vitamin K2) and Bone Quality in the Treatment of Postmenopausal Osteoporosis." Nutrition Reviews 2006;64(12):509-517." 01/01/2014 - "Eligible Chinese women with postmenopausal osteoporosis (N=236) were randomized to Group M or Group A and received menatetrenone 45 mg/day or alfacalcidol 0.5 μg/day, respectively, for 1 year. "

Related Drugs and Biologics

1.	Vitamin K 2 (Vitamin K2)
2.	Vitamin D
3.	Calcium
4.	Risedronic Acid (Actonel)
5.	Diphosphonates (Bisphosphonates)
6.	Vitamin K
7.	Vitamin K 1 (Phylloquinone)
8.	menaquinone 7
9.	Etidronic Acid (HEDP)
10.	alfacalcidol

Related Therapies and Procedures

1.	Therapeutics
2.	Hepatectomy
3.	Ovariectomy (Oophorectomy)
4.	Oral Administration
5.	Gastrectomy